The Recombinant Zoster vaccine (RZV, commercially known as SHINGRIX TM) offers strong protection against shingles, but there’s still a lot we don’t understand about how the immune system prevents ...

Who should get it? Wen: The US Centers for Disease Control and Prevention recommends two doses of the recombinant zoster vaccine, called Shingrix, for adults 50 and older . This age recommendation ...

A recent study found that people who received Zostavax, a older shingles vaccine, had a lower risk of developing dementia.

Women at risk for Alzheimer’s and other causes of dementia may especially benefit from the vaccine, a new study finds.

Questions are answered by experts at the Oregon Health Authority, other state agencies or community partners. Questions and answers are republished by permission.

GSK Plc is studying a large group of elderly adults in the UK to determine if its blockbuster shingles vaccine reduces the risk of dementia, potentially opening the door to an expanded label for the ...

At that point, adults aged 65 became eligible to receive Shingrix, while adults aged 66 at the time have to wait until they turn 70 to take the vaccine. Because age at the time of the program’s ...

GSK is enlisting the aid of China’s Chongqing Zhifei Biological Products (Zhifei) to drive sales of its most important vaccine, Shingrix, in China over the next few years, and may also call upon ...

Then, in 2024, researchers at the University of Oxford in England found an even stronger protective effect from the DNA-based vaccine, Shingrix. The study authors, led by Maxime Taquet ...

The four-year project will seek to confirm mounting evidence the Shingrix vaccine – already available on the NHS – cuts the risk of dementia by up to 27 per cent compared with an older ...